. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party . J Clin Oncol 2005 ; 23 : 9219
Kenneth Anderson
Studies reported in 2013 can help clinicians better manage multiple myeloma, while anticipating even better treatments and outcomes after drugs currently in the pipeline become available, according to Kenneth Anderson, MD, Kraft Family Professor
Yvonne A. Efebera and Nina Shah
Continuous Therapy Offers Survival Advantage, But Questions Remain In the past 5 years alone, 6 drugs have been FDA-approved for the treatment of multiple myeloma (MM). Despite significant improvements in progression-free survival (PFS) and overall
William I. Bensinger
): 186 – 190 . 2 Gahrton G Svensson H Björkstrand B . Syngeneic transplantation in multiple myeloma — a case-matched comparison with autologous and allogeneic
Huntsman Cancer Institute at the University of Utah
Multiple myeloma will account for an estimated 16,570 new cancer cases in the United States in 2006, with an estimated 11,310 deaths. It is not currently considered curable; however, treatment has evolved rapidly because of new drugs such as bortezomib, thalidomide, and lenalidomide. In addition, increased understanding of the bone marrow microenvironment is creating rationale for new combinations and new drug development. Important updates in the 2007 NCCN guidelines include new recommended single-agent and combination regimens for consideration for induction and salvage therapy.
For the most recent version of the guidelines, please visit NCCN.org
Jean-Luc Harousseau and Philippe Moreau
. Attal M Harousseau JL Stoppa AM . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome . N Engl J Med 1996 ; 335 : 91 – 97 . 2. Child JA Morgan GJ
Sundar Jagannath
Hematologists/oncologists and other physicians can expect to encounter an increasing number of patients with multiple myeloma (MM) in the coming years. Between 1997 and 2006, the incidence rate of myeloma declined in the United States, but the
Philip L. McCarthy
Multiple myeloma (MM) is an incurable disease. One major goal in the treatment of patients with MM is to improve progression-free and overall survival (PFS and OS, respectively). In the past 10 years, the median OS for patients with MM has
Alexandra K. Zaleta, Melissa F. Miller, Julie S. Olson, Eva Y.N. Yuen, Thomas W. LeBlanc, Craig E. Cole, Shauna McManus and Joanne S. Buzaglo
Background Multiple myeloma (MM), a plasma cell malignancy, is the second most common hematologic cancer in the United States, with an estimated 32,110 new cases occurring in 2019, and an estimated 12,960 deaths. 1 Advances in treatment using
Multiple myeloma will account for an estimated 15,270 (1.1%) new cancer cases in the United States in the year 2004, including 8,090 cases in men (1.2%) and 7,180 (1.1%) cases in women. It will also be responsible for approximately 11,070 (2.0%) cancer deaths in 2004. Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable at present. However, treatment algorithms such as this one (based on published data and clinical experience) can optimize therapy, not only for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.
For the most recent version of the guidelines, please visit NCCN.org
